** Shares of drug developer Viking Therapeutics VKTX.O fall 8% to $30.82 premarket
** Co reported quarterly earnings in Wednesday, in which it also said its late-stage trial for the subcutaneous or under-the-skin version of experimental obesity drug VK2735 will start in Q2
** Investors were hoping for some meaningful developments, but the updates were mostly incremental, which sent shares lower - brokerage J.P.Morgan
** J.P.Morgan and another brokerage Oppenheimer say update was largely inline with expectations, although some investors were anticipating an earlier trial initiation
** Shares more than doubled in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。